Therapeutic drug monitoring and pharmacogenetic, study of HIV-infected ethnic chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lee, Kuan Yeh ^a   Lin, Shu Wen ^a,b   Sun, Hsin Yun ^a   Kuo, Ching Hua ^a,b   Tsai, Mao Song ^c   Wu, Bing Ru ^d   Tang, Sue Yo ^b   Liu, Wen Chun ^a   Chang, Sui Yuan ^a,d   Hung, Chien Ching ^a,e,f  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RIFAMPICIN;

ADULT; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG USE; ETHNICITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOXAZINES; BODY WEIGHT; CHINA; DRUG MONITORING; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIFAMPIN; TUBERCULOSIS; YOUNG ADULT;

EID: 84895816315     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088497     Document Type: Article

References (27)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents (2013) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed: 16 June 2013.
2. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, et al. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15: 71-75. (Pubitemid 32055781)
3. Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, et al. (2006) Interpatient variability in the pharmacokinetics of the HIV nonnucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 61: 148-154. (Pubitemid 43382608)
4. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, et al. (2003) Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 47: 130-137. (Pubitemid 36070353)
5. Stohr W, Back D, Dunn D, Sabin C, Winston A, et al. (2008) Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 13: 675-685.
6. Poeta J, Linden R, Antunes MV, Real L, Menezes AM, et al. (2011) Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. J Antimicrob Chemother 66: 2601-2604.
7. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, et al. (2009) CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 53: 863-868.
8. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, et al. (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18: 2391-2400. (Pubitemid 40065906)
9. Food and Drug Administration. Sustiva labeling update/dosing adjustment with rifampin. Available: http://www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/HIVandAIDSActivities/ucm294476.htm. Accessed: 16 June 2013.
10. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, et al. (2013) Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis 57: 586-593.
11. Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers [abstract 42280]; 1998 June 28-July 3; Geneva, Switzerland.
12. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, et al. (2002) Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41: 681-690.
13. Nyakutira C, Roshammar D, Chigutsa E, Chonzi P, Ashton M, et al. (2008) High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64: 357-365.
14. Uttayamakul S, Likanonsakul S, Manosuthi W, Wichukchinda N, Kalambaheti T, et al. (2010) Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB coinfected Thai adults. AIDS Res Ther 7: 8.
15. Guan S, Huang M, Chan E, Chen X, Duan W, et al. (2006) Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 29: 14-21. (Pubitemid 44279393)
16. Ramachandran G, Kumar AK, Swaminathan S, Venkatesan P, Kumaraswami V, et al. (2006) Simple and rapid liquid chromatography method for determination of efavirenz in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 835: 131-135.
17. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, et al. (2009) Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G> T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 14: 687-695.
18. Kwara A, Lartey M, Sagoe KW, Court MH (2011) Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25: 388-390.
19. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526. (Pubitemid 350116943)
20. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, et al. (2011) Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 66: 2092-2098.
21. Cho JY, Lim HS, Chung JY, Yu KS, Kim JR, et al. (2004) Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab Dispos 32: 1341-1344.
22. Hiratsuka M, Takekuma Y, Endo N, Narahara K, Hamdy SI, et al. (2002) Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 58: 417-421.
23. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, et al. (2005) Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 192: 1931-1942. (Pubitemid 41681891)
24. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, et al. (2008) Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 48: 1032-1040.
25. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, et al. (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45: 1230-1237. (Pubitemid 47580326)
26. Manosuthi W, Sungkanuparph S, Tantanathip P, Mankatitham W, Lueangniyomkul A, et al. (2009) Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother 53: 4545-4548.
27. Borand L, Laureillard D, Madec Y, Chou M, Pheng P, et al. (2013) Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg. Antivir Ther 18: 419-423.